The risk of cutaneous adverse reactions among patients with the HLA-A* 31: 01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: A perspective review

Therapeutic Advances in Drug Safety

Volumn 4, Issue 6, 2013, Pages 246-253

  Kaniwa, Nahoko ^a   Saito, Yoshiro ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Biomarker; HLA genotype; hypersensitivity syndrome; Stevens Johnson syndrome; toxic epidermal necrolysis

Indexed keywords

BIOLOGICAL MARKER; CARBAMAZEPINE; ESLICARBAZEPINE; OXCARBAZEPINE;

ADVERSE DRUG REACTION; ALLELE; CUTANEOUS ADVERSE DRUG REACTION; ETHNIC GROUP; GENE FREQUENCY; GENOTYPE; HLA SYSTEM; HUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING; SKIN DISEASE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EID: 84898882136     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098613499791     Document Type: Review

References (37)

1. Adam J. Pichler W. Yerly D. (2011) Delayed drug hypersensitivity: models of T-cell stimulation. Br J Clin Pharmacol 71: 701–707.
2. Amstutz U. Ross C. Castro-Pastrana L. Rieder M. Shear N. Hayden M. (2013) HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther 94: 142–149.
3. Aoki M. Hosono N. Takata S. Nakamura Y. Kamatani N. Kubo M. (2012) New pharmacogenetic test for detecting an HLA-A*31:01 allele using the InvaderPlus assay. Pharmacogenet Genomics 22: 441–446.
4. Bastuji-Garin S. Rzany B. Stern R. Shear N. Naldi L. Roujeau J. (1993) Clinical classification of cases of toxic epidermal necrolysis, Stevens–Johnson syndrome, and erythema multiforme. Arch Dermatol 129: 92–96.
5. Buggy Y. Layton D. Fogg C. Shakir S. (2010) Safety profile of oxcarbazepine: results from a prescription-event monitoring study. Epilepsia 51: 818–829.
6. Chen P. Lin J. Lu C. Ong C. Hsieh P. Yang C. (2011) Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 364: 1126–1133.
7. Chung W. Hung S. Hong H. Hsih M. Yang L. Ho H. (2004) Medical genetics: a marker for Stevens–Johnson syndrome. Nature 428: 486.
8. Dogan E. Usta B. Bilgen R. Senol Y. Aktekin B. (2008) Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy. Epilepsy Behav 13: 156–161.
9. Hashimoto K. (2006) Drug induced hypersensitivity syndrome. In Shiohara T. Miyaji Y. Takigawa M. (eds), Dermatology Practice 19, Insight into Skin Rash. Tokyo: Bunkoudo.
10. He N. Min F. Shi Y. Guo J. Liu X. Li B. (2012) Cutaneous reactions induced by oxcarbazepine in Southern Han Chinese: incidence, features, risk factors and relation to HLA-B alleles. Seizure 21: 614–618.
11. Hu F. Wu X. An D. Yan B. Stefan H. Zhou D. (2011) Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population. Seizure 20: 160–162.
12. Hung S. Chung W. Jee S. Chen W. Chang Y. Lee W. (2006) Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 16: 297–306.
13. Hung S. Chung W. Liu Z. Chen C. Hsih M. Hui R. (2010) Common risk allele in aromatic antiepileptic-drug induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 11: 349–356.
14. Jenkins R. Meng X. Elliott V. Kitteringham N. Pirmohamed M. Park B. (2009) Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HSA in vitro and in vivo. Proteomics Clin 3: 720–729.
15. Kaniwa N. Saito Y. Aihara M. Matsunaga K. Tohkin M. Kurose K. (2010) HLA-B*1511 is a risk factor for carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 51: 2461–2465.
16. Kashiwagi M. Aihara M. Takahashi Y. Yamazaki E. Yamane Y. Song Y. (2008) Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients. J Dermatol 35: 683–685.
17. Kim S. Lee K. Song W. Kim S. Jee Y. Lee S. (2011) Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res 97: 190–197.
18. Ko T. Chung W. Wei C. Shih H. Chen J. Lin C. (2011) Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens–Johnson syndrome. J Allergy Clin Immunol 128: 1266–1276.
19. Kulkantrakorn K. Tassaneeyakul W. Tiamkao S. Jantararoungtong T. Prabmechai N. Vannaprasaht S. (2011) HLA-B*1502 strongly predicts carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. Pain Pract 12: 202–208.
20. Kurose K. Sugiyama E. Saito Y. (2012) Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet 27: 9–54.
21. Le Louët H. Thomas L. Babai S. (2008) DRESS: is oxcarbazepine safer than carbamazepine? An analysis of the French Pharmacovigilance database. Eur J Neurol 15: e43.
22. Locharernkul C. Loplumlert J. Limotai C. Korkij W. Desudchit T. Tongkobpetch S. (2008) Carbamazepine and phenytoin induced Stevens–Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 49: 2087–2091.
23. Lonjou C. Thomas L. Borot N. Ledger N. de Toma C. LeLouet H. (2006) A marker for Stevens–Johnson syndrome …: ethnicity matters. Pharmacogenomics J 6: 265–268.
24. Man C. Kwan P. Baum L. Ledger N. de Toma C. LeLouet H. (2007) Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48: 1015–1018.
25. McCormack M. Alfirevic A. Bourgeois S. Farrell J. Kasperavičiūtė D. Carrington M. (2011) HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Eng J Med 364: 1134–1143.
26. Mehta T. Prajapati L. Mittal B. Joshi C. Sheth J. Patel D. (2009) Association of HLA-B*1502 allele and carbamazepine-induced Stevens–Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 75: 579–582.
27. Monshi M. Faulkner L. Gibson A. Jenkins R. Farrell J. Earnshaw C. (2013) Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 57: 727–739.
28. Naisbitt D. Britschgi M. Wong G. Farrell J. Depta J. Chadwick D. (2003) Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 63: 732–741.
29. Niihara H. Kakamu T. Fujita Y. Kaneko S. Morita E. (2012) HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol 39: 594–601.
30. Ozeki T. Mushiroda T. Yowang A. Takahashi A. Kubo M. Shirakata Y. (2011) Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 20: 1034–1041.
31. Robinson J. Mistry K. McWilliam H. Lopez R. Parham P. Marsh S. (2011) The IMGT/HLA database. Nucleic Acids Res 39(Suppl. 1): D1171–F1176.
32. Tassaneeyakul W. Tiamkao S. Jantararoungtong T. Chen P. Lin S. Chen W. (2010) Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 51: 926–930.
33. Uchiyama K. Kubota F. Ariyoshi N. Matsumoto J. Ishii I. Kitada M. (2013) Development of a simple method for detection of HLA-A*31:01 allele. Drug Metab Pharmacokinet 12 February (Epub ahead of print).
34. Wang Q. Zhou J. Zhou L. Chen Z. Fang Z. Chen S. (2011) Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure 20: 446–448.
35. Wei C. Chung W. Huang H. Chen Y. Hung S. (2012) Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens–Johnson syndrome. J Allergy Clin Immunol 129: 1562–1569.
36. Yip V. Marson A. Jorgensen A. Pirmohamed M. Alfirevic A. (2012) HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther 92: 757–765.
37. Zhang Y. Wang J. Zhao L. Peng W. Shen G. Xue L. (2011) Strong association between HLA-B*1502 and carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol 67: 885–887.